Chordate interview: CEO Anders Weilandt on the new trademark – Ozilia®

Biostock interviews Chordate Medical’s CEO Anders Weilandt about the new Ozilia® brand, which is the next step in the commercialization project of the company’s migraine treatment, and which will be launched at the International Headache Congress in Seoul September 14-17.

 “It will be incredibly exciting to present Ozilia and our unique technology for preventive migraine treatment without drugs. The global leaders in migraine care, research and industry are gathered at this congress, which is our first international exhibition. Our expectation is to be able to create many good contacts to support the commercialisation project.  

Read the full article

More posts

For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of Ozilia® Migraine, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

Contact us

  • This field is for validation purposes and should be left unchanged.

The information is handled according to our privacy policy